RBC Capital raised the firm’s price target on Sage Therapeutics to $63 from $60 and keeps an Outperform rating on the shares. The company’s launch plan for Zuranolone continues to be refined, and there is a high – 75%-80% – probability of approval that is further de-risked by the recent announcement of no AdComm meeting, the analyst tells investors in a research note. RBC adds that it expects significant initial uptake of zuranolone with differentiation in rapidity of effect and clean safety.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on SAGE:
- Is SAGE a Buy, Before Earnings?
- Sage Therapeutics participates in a conference call hosted by Piper Sandler
- RBC upgrades Sage Therapeutics on doctor survey, share selloff
- Sage Therapeutics upgraded to Outperform from Sector Perform at RBC Capital
- No ad com suggests positive potential outcome for Sage’s zura, says BofA
